ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study

Andrea K. Steck, Alexandra Fouts, Dongmei Miao, Zhiyuan Zhao, Fran Dong, Jay M Sosenko, Peter Gottlieb, Marian J. Rewers, Liping Yu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies. Materials and Methods: TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits. Results: After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed higher affinity at the initial visit, and affinity results stayed consistent over time. No converting events from low to high or high to low affinity were seen over time. Conclusions: Confirmed positivity for ECL is associated with high affinity and can help staging of risk for type 1 diabetes in single autoantibody-positive subjects.

Original languageEnglish (US)
Pages (from-to)410-414
Number of pages5
JournalDiabetes Technology and Therapeutics
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Glutamate Decarboxylase
Autoantibodies
Type 1 Diabetes Mellitus
Insulin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. / Steck, Andrea K.; Fouts, Alexandra; Miao, Dongmei; Zhao, Zhiyuan; Dong, Fran; Sosenko, Jay M; Gottlieb, Peter; Rewers, Marian J.; Yu, Liping.

In: Diabetes Technology and Therapeutics, Vol. 18, No. 7, 01.07.2016, p. 410-414.

Research output: Contribution to journalArticle

Steck, Andrea K. ; Fouts, Alexandra ; Miao, Dongmei ; Zhao, Zhiyuan ; Dong, Fran ; Sosenko, Jay M ; Gottlieb, Peter ; Rewers, Marian J. ; Yu, Liping. / ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. In: Diabetes Technology and Therapeutics. 2016 ; Vol. 18, No. 7. pp. 410-414.
@article{274632940b3d4304876acf8193d422a7,
title = "ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study",
abstract = "Background: Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies. Materials and Methods: TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits. Results: After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed higher affinity at the initial visit, and affinity results stayed consistent over time. No converting events from low to high or high to low affinity were seen over time. Conclusions: Confirmed positivity for ECL is associated with high affinity and can help staging of risk for type 1 diabetes in single autoantibody-positive subjects.",
author = "Steck, {Andrea K.} and Alexandra Fouts and Dongmei Miao and Zhiyuan Zhao and Fran Dong and Sosenko, {Jay M} and Peter Gottlieb and Rewers, {Marian J.} and Liping Yu",
year = "2016",
month = "7",
day = "1",
doi = "10.1089/dia.2015.0316",
language = "English (US)",
volume = "18",
pages = "410--414",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study

AU - Steck, Andrea K.

AU - Fouts, Alexandra

AU - Miao, Dongmei

AU - Zhao, Zhiyuan

AU - Dong, Fran

AU - Sosenko, Jay M

AU - Gottlieb, Peter

AU - Rewers, Marian J.

AU - Yu, Liping

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies. Materials and Methods: TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits. Results: After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed higher affinity at the initial visit, and affinity results stayed consistent over time. No converting events from low to high or high to low affinity were seen over time. Conclusions: Confirmed positivity for ECL is associated with high affinity and can help staging of risk for type 1 diabetes in single autoantibody-positive subjects.

AB - Background: Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies. Materials and Methods: TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits. Results: After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed higher affinity at the initial visit, and affinity results stayed consistent over time. No converting events from low to high or high to low affinity were seen over time. Conclusions: Confirmed positivity for ECL is associated with high affinity and can help staging of risk for type 1 diabetes in single autoantibody-positive subjects.

UR - http://www.scopus.com/inward/record.url?scp=84978042649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978042649&partnerID=8YFLogxK

U2 - 10.1089/dia.2015.0316

DO - 10.1089/dia.2015.0316

M3 - Article

C2 - 26991969

AN - SCOPUS:84978042649

VL - 18

SP - 410

EP - 414

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 7

ER -